Hence, in the current study, we examined the efficacy of a novel mRNA lipid nanoparticle based approach for the in situ delivery and production of IL-12 (IL-12-LNP) in suppressing tumor progression in a primary transgenic mouse model of refractory MYC-driven hepatocellular carcinoma (HCC, [25]). Here, MYC is linked to hepatocellular carcinoma.